Results 91 to 100 of about 1,805,472 (279)

Social-economic burden of Pompe disease with late onset in the Russian Federation

Качественная клиническая практика, 2019
Pompe disease (PD) — a rare disease with progressive muscles weakness, cardiac and pulmonary insufficiency and others vital life-threatening symptoms without enzyme replacement therapy (ERT).
A. S. Kolbin, I. A. Vilyum, Yu. E. Balikina, M. A. Proskurin, O. I. Karpov   +4 more
doaj   +1 more source

Direct medical costs of diabetes and its complications in Vietnam: a national health insurance database study.

Diabetes Research and Clinical Practice, 2020
AIM To estimate the direct medical cost of type 2 diabetes mellitus (T2DM) and its complications in Vietnam. METHODS Using the public payer perspective, the direct medical cost was estimated using routine data in the national claims database in Vietnam
Huy Tuan Kiet Pham, Thi Tuyet Mai Kieu, Tuan Duc Duong, Khoa Dieu Van Nguyen, Quang Nam Tran, Tien Hung Tran, Junice Yi Siu Ng   +6 more
semanticscholar   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Analisis Efektivitas Biaya Penggunaan Antara Metformin dan Glimepiride Pada Penderita Diabetes Melitus Tipe 2 Rawat Jalan di Rumah Sakit PKU Muhammadiyah Delanggu 2016 [PDF]

, 2018
In 2013 diabetes has caused 5.1 million deaths worldwide. Indonesia ranked 7th of 10 countries with the highest diabetics in 2013. In 2011 the cost of DM therapy reached USD 465 billion, and expected to increase by USD 595 billion in 2030.
, Mariska Sri Harlianti, M.Sc., Apt., Romadhoni, Hurin’in Amalia   +1 more
core  

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

Molecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen, Lucrezia De Santis, Bret M. Stephens, Vincent Bernard, Jörg C. Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A. Guerrero, Alexander Semaan   +11 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Measuring Selection Incentives in Managed Care: Evidence from the Massachusetts State Employee Insurance Program [PDF]

Health economists and policymakers have long recognized that capitation gives insurers incentive to manipulate their offerings to deter the sick and attract the healthy.
Anupa Bir, Karen Eggleston
core  

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source